PEDIALYTE FREEZER POPS OTC
Generic Name and Formulations:
Dextrose 1.6g, sodium 2.8mEq, potassium 1.25mEq, chloride 2.2mEq, Calories 6.25; per 62mL pop; grape, cherry, orange, or raspberry flavored; contains acesulfame.
Indications for PEDIALYTE FREEZER POPS:
Oral fluid and electrolyte replacement in mild to moderate diarrhea and vomiting.
Give frozen pop or unfrozen as a drink, with other fluid and electrolyte supplements. <1yr: not recommended. ≥1yr: give as desired by patient.
As sole therapy in severe continuing diarrhea. Intractable vomiting. Adynamic ileus. Intestinal obstruction or perforated bowel. Anuria, oliguria, or impaired homeostatic mechanism.
Fluid & electrolyte replacement.
Liq (flavored)—1L; Liq (unflavored)—2oz, 1L; Singles (6.8oz)—16; Pwd (packets)—4, 8; Pops—16
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy